Early stage technology advisor, Acceleris Capital, has marked a strong start to 2019 with a National award win at ‘The Great EIS 25th Anniversary Awards Banquet’. This follows the completion of two early stage deals for regional companies.
The Greater Manchester headquartered corporate finance advisory firm, has been recognised with the award for Outstanding Contribution to EIS Business Services over a long period of time, at the EIS Anniversary Banquet, beating numerous nationwide firms. The Enterprise Investment Scheme is a government initiative to encourage private investment in to small business looking to grow and scale. Across 25 years, the scheme has raised over £20bn for small businesses.
Corporate Finance Director Patrick Molyneux comments,
“To be recognised by our peer group is always pleasing but to receive a milestone award spanning 25 years is very satisfying. Our team take great pride in continuing to be creative, pragmatic and knowledgeable about our market. Early stage companies are exciting to work with but difficult to plan for as there are several unknowns, so the more education we can provide about the risks of this space and how to mitigate them, the better informed investors can be.”
“We focus on innovative companies with an ambition for global scale and potential for positive impact. Due to the high-risk nature of such technologies, a lot of investors tend to ignore this space as part of their wider portfolios. This is a gap we are looking to fill and what EIS has always been designed for – to mitigate those risks.”
Mark Brownridge, Director General of the EISA, said: “The event saw some of the most prominent members of the early stage business investment community come together to celebrate the success and future of the Enterprise Investment Scheme. Acceleris displayed excellent client referencing, impressive regional impact with high quality support of companies through their life cycle. Acceleris has demonstrated time and time again that they know the EIS market inside out and have consistently innovated and evolved for the benefit of their clients. Their impact over a sustained period of time saw them nose ahead of some other strong entries.”
This prestigious award has followed the completion of two deals for early stage companies. Acceleris advised the Company and arranged a syndicate including institutions and High-Net-Worth investors to a follow-on fundraise for BiVictriX Therapeutics Limited, based at Alderley Park. BiVictriX are aiming to eliminate toxicity in blood cancer therapeutics and has potential for a considerable positive impact. The company continues to achieve each milestone in its development on time and under budget which is rare for a biotech company.
Acceleris has also advised on the completion of a £750k investment into Reacta Biotech Limited by the Development Bank of Wales, Perscitus Advisors and High Net Worth individuals. Reacta is commercialising the work of World-leading experts from the University of Manchester on food allergy diagnostics and management. With revenues secured in the UK, USA and Canada, the Company has relocated to a new manufacturing facility in North-Wales and is now raising further significant capital to expand.
Molyneux continues, “We intend to communicate to the investor market that a small % of investable wealth should be considered towards commercialising impactful technologies. We believe that by providing constant and coherent advice to these companies throughout their growth cycle, improves their chances of success and mitigates risk.”
